Targeting a key process in ovarian cancer that resists chemotherapy
Targeting RNA Polymerase I Transcription Machinery in Chemoresistant Ovarian Cancer
This study is looking at how some ovarian cancer tumors manage to survive chemotherapy and is testing new treatments that could help make those stubborn cancer cells easier to kill, so patients can have better outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-10796986 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind chemoresistance in epithelial ovarian cancer, particularly focusing on how certain tumors adapt to evade the effects of chemotherapy. By analyzing samples from patients before and after chemotherapy, as well as using patient-derived models, the study aims to identify the role of RNA Polymerase I in the production of ribosomal RNA, which is crucial for cancer cell survival. The researchers are testing specific inhibitors that target this process to see if they can effectively kill resistant cancer cells and improve treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with recurrent epithelial ovarian cancer who have shown resistance to standard chemotherapy treatments.
Not a fit: Patients with early-stage ovarian cancer who have not yet undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that effectively target and eliminate chemoresistant ovarian cancer cells.
How similar studies have performed: Other research has shown promising results in targeting ribosomal biogenesis in cancer, suggesting that this approach may be effective in treating chemoresistant ovarian cancer.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Landen, Charles Nicholson — University of Virginia
- Study coordinator: Landen, Charles Nicholson
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.